Surgical Science Sweden AB (publ) (OM:SUS) entered into a definitive agreement to acquire Simbionix USA Corporation from 3D Systems, Inc. for approximately $310 million on July 28, 2021. Surgical Science acquires 100 shares of 3D.The purchase price of $305 million is subject to customary closing conditions and adjustments. At Closing Surgical Science will have sufficient cash on hand or other sources of immediately available funds that together enable it to make payment of the Purchase Price. Through this transaction, Simbionix will be integrated with Surgical Science. Simbionix reported sales of $40.8 million in 2020. The Simbionix team will now join forces with Surgical Science. The proceeds from this transaction, combined with previously announced divestitures, will leave 3D Systems with a cash balance of approximately $500 million and no debt. The Closing is not subject to a financing condition. Surgical Science has obtained voting agreements or intent letters from the holders of at least the percentage of shares of outstanding shares of Surgical Science required to obtain the Surgical Science’s Shareholder Approval and a general meeting of Surgical Science is held as to approve the Transactions. The transaction is expected to close in August 2021. Pareto Securities AB acted as financial advisor to Surgical Science Sweden AB. Steven Haas and Gary Thompson of Winston & Strawn LLP, Erdinast, Ben-Nathan & Co., Forssander Sonander Advokat AB, Advokatfirman Vinge KB acted as legal advisor to Surgical Science Sweden AB. PwC acted as due diligence provider to Surgical Science Sweden AB. Gary E. Thompson and Steven M. Haas of Hunton Andrews Kurth LLP and Chaim Friedland, Yoni Raff, Assaf Prussak of Gornitzky & Co. acted as legal advisors to 3D system and Simbionix USA Corporation.